SGP Overview

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company develops a non-bioerodible drug delivery technology, designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System) is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma or ocular hypertension.

Wall Street analysts forecast SGP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

SpyGlass Pharma Inc revenue for the last quarter amounts to NaN USD, decreased

SpyGlass Pharma Inc. EPS for the last quarter amounts to USD, decreased

SpyGlass Pharma Inc (SGP) has 0 emplpoyees as of March 03 2026.

Today SGP has the market capitalization of 890.57M USD.